Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8807107 | 0.89 | ALDH1A1 (0.39) | ALDH1A1TSHRTDP1HTTSMN1; SMN2 | |
| SCHEMBL5983928 | 0.76 | ALDH1A1 (0.33) | ALDH1A1TSHRTDP1 | |
| SCHEMBL4731276 | 0.70 | ESRRA (0.38) | LMNA | |
| SCHEMBL8903140 | 0.70 | TNFRSF1A (0.40) | CA1CA2 | |
| SCHEMBL4394260 | 0.70 | DHFR (0.34) | — | |
| SCHEMBL9161090 | 0.69 | DHFR (0.38) | ALDH1A1TSHRLMNACYP3A4 | |
| SCHEMBL1729127 | 0.69 | PTGDR2 (0.37) | ALDH1A1HTTSMN1; SMN2LMNAALOX15 | |
| SCHEMBL7987373 | 0.69 | TNFRSF1A (0.37) | LMNACA1CA2 | |
| SCHEMBL8779698 | 0.69 | EGFR (0.48) | ALDH1A1TSHRTDP1L3MBTL1LMNA | |
| SCHEMBL9162907 | 0.69 | TSHR (0.42) | ALDH1A1TSHRHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215646-A1 | Methods for treating multiple sclerosis and pharmaceutical compositions therefor | RENOVIS, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005087214-A1 | METHODS FOR TREATING MULTIPLE SCLEROSIS AND PHARMACEUTICAL COMPOSITIONS THEREFOR | RENOVIS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215646-A1 | Methods for treating multiple sclerosis and pharmaceutical compositions therefor | CCL11, TXNRD3, CX3CR1 | ALDH1A1 1148/4885TSHR 2915/4885TDP1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.